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This review aims to provide a snapshot of the actual state of knowledge on genetic variants of nuclear receptors (NR) involved in
regulating important aspects of liver metabolism. It recapitulates recent evidence for the application of NR in genetic diagnosis of
monogenic (“Mendelian”) liver disease and their use in clinical diagnosis. Genetic analysis of multifactorial liver diseases such as
viral hepatitis or fatty liver disease identiﬁes key players in disease predisposition and progression. Evidence from these analyses
pointstowardsaroleofNRpolymorphismsincommondiseases,linkingregulatorynetworkstocomplexandvariablephenotypes.
The new insights into NR variants also oﬀer perspectives and cautionary advice for their use as handles towards diagnosis and
treatment.
1.Introduction
Systematically, genetic analysis with regard to disease onset
and progression can be separated into pre- and post-hoc ex-
amination of monogenic or polygenic diseases. Monogenic
(“Mendelian”) diseases are caused by a single gene defect
and follow relatively straightforward inheritance patterns.
The most prominent of these disorders are rather rare, often
severe, and characterized by early onset. Genetic testing for
monogenic liver disease in symptomatic patients is based on
known disease-associated gene variants, thereby conﬁrming
the genetic etiology and sometimes allowing prediction of
disease progression [1].
In contrast, polygenic diseases such as fatty liver disease
and gallstones result from combinations of multiple gene
variants andenvironmental factors,allof whichplay a role in
diseaseinitiationandprogression[2].Theassessmentofpre-
disposition towards polygenic disease is based on sequence
analysis of known contributory genes and construction of
“polygenic risk scores” from variants of these genes [1]. Still
initsinfancy,personalgenomeinformationmighteventually
beabletopredictavarietyofrisksassociatedwithanindivid-
ual’s lifestyle such as fatty food and alcohol consumption, as
well as susceptibility to infectious diseases such as infection
with hepatitis B or C virus.
2.NuclearReceptors
Nuclear receptors (NRs) are a subclass of regulatory mole-
cules that orchestrate gene transcription in response to the
presence or absence of speciﬁc ligands. Due to these func-
tionalrequirements,theyarecharacterizedbythepresenceof
a ligand-binding and a DNA-binding domain. NRs represent
a central point of interaction between environment and gene
regulation. They are the “hinge” connecting endogenous and
environmental stimuli, that is, ligands, with the cells’ tran-
scriptional response (Figure 1).
This position makes them a prime target for medical
interventionbyagonisticorantagonisticbindingofsynthetic
compounds. However, the regulatory orchestra of molecules
conducted by NR is highly complex and abounds with
redundancyandcrosstalk,henceanyimpactmightbepoten-
tially diﬃcult to predict as well as disappointingly diﬀuse.
Even identical variations in a single NR can result in a wide
variety of phenotypes due to genetic diﬀerences in the cofac-
tors involved and higher order networks based on mutual
regulatory interaction [3].
The core position in maintaining cellular equilibrium
should render NR susceptible to the impact of natural se-
quence variation. On the other hand, it has been suggested
thatthephenotypiceﬀectsofNRgenevariationareboundto2 Journal of Lipids
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Figure 1: Schematic depiction of NR action in hepatocytes demonstrating a reduction in complexity and an increase in penetrance of
genetic variants from the sinus to the canaliculus. Squares represent metabolic compounds such as triglycerides, cholesterol, fatty acids,
and phospholipids; triangles represent bile salts; stars represent toxins; large semi-circles symbolise nuclear receptors, and circles stand for
metabolic enzymes.
be less severe than a variation in functionally deﬁned eﬀector
molecules such as a single-substrate transmembrane trans-
porter. The transcriptional regulation directed by NR is kept
in tight check and ﬁne-tuned by a set of co-regulators (co-
activators or corepressors) [4, 5]. Consequently, relatively
few congenital, “Mendelian” diseases have been identiﬁed
to date, which are caused by genetic variations in NR. One
example is maturity-onset diabetes of the young (MODY1),
caused by mutations aﬀecting the gene encoding the hepatic
n u c l e a rf a c t o r( H N F )4 - a l p h a( NR2A1)[ 6]( Table 1).
While the denominator of “monogenic disease” seems to
imply a straightforward genotype-to-phenotype correlation,
the reality in even those seemingly “simple” diseases is
anything but simple: Tirona et al. [7] showed that HNF4A is
critically involved in the PXR (NR1I2)- and CAR (NR1I3)-
mediated transcriptional activation of cytochrome P450
(CYP) 3A4, hence involving two more NRs even in its
basal regulatory function. Whereas Hani et al. [8] identiﬁed
HNF4A mutations as being causative in maturity-onset
diabetesoftheyoung(MODYtype1,OMIM#125850)based
on a nonsense mutation (p.Q268X) in an extended pedigree,
many other seemingly functional variants have turned out to
be either innocent bystanders or of relatively low penetrance.
Pearson et al. [9] were able to show that functional HNF4A
variants are associated with a considerable increase in birth
weight and macrosomia, and a novel causeof neonatal hypo-
glycemia. Results from the investigation of 108 members of
15 families with MODY1 show how genotype-phenotype
correlation is far from clearcut, with both described phe-
notypes being found only in 15–56% of mutation carriers.
Ek et al. [10] examined the impact of two disease-associated
variants (p.T130I and p.V255M, Table 1) on various aspects
of HNF4-alpha function. Both variants showed decreased
transactivation. Only the p.T130I polymorphism was
associated with T2D, whereas the p.V255M variant was
associated with a decrease in fasting serum C-peptide levels.
Array analyses revealed that HNF4-alpha bound to the
promoters of 12% of hepatocyte islet genes represented
on a microarray and hence can be considered a “master
regulator” of hepatocyte and beta-cell genes [11]. But even
in a complex and occasionally ambiguous setting, where the
detection of a functional variant does not necessarily predict
disease phenotypes, genetic testing appears to be helpful,
if only to identify at-risk relatives and motivate aﬀected
individuals towards lifestyle changes [12]. Evidently, there is
no clear delineation between the “Mendelian” diseases and
contribution towards complex phenotypes modulated by
NRvariants(Figure 1).Ameta-analysisofpolymorphismsinJournal of Lipids 3
Table 1: Single nucleotide polymorphisms (SNPs) associated with liver disease.
Gene SNP rs number Disease OR (95% CI) P-value Cohort
(controls) Population Reference
HNF4a (NR2A1) Q268X rs6093980 MODY-1 N/A N/A >360 R-W pedigree [6]
Y16X N/A N/A N/A 108 UK [9]
S34X
R127W
D206Y
E276Q
R303H
I314F
L332P
M364R
c. IVS5nt+1G>A
c.IVS4nt-2A>G
T(3;20)
V393I N/A NIDDM N/A N/A N/A F-40 pedigree [8]
T130I N/A T2D 1.26
(1.01–1.57) 0.04 1,466 (4,520) Danish [10]
V255M N/A
Decreasing
fasting serum
C-peptide levels
1.0
(0.28–3.65) 1.0
FXR (NR1H4) −20,647T>G N/A Gallstones 0.42
(0.17–1.01) 0.053 77 (74) Mexican [34]
−1G>T rs56163822 0.25
(0.07–0.95) 0.042 75 (70)
IVS7-31A>T rs7138843 0.47
(0.22–1.01) 0.053 77 (88)
−1G>T rs56163822 ICP 0.92
(0.35–2.44) 0.96 342 (349) British/Swedish [35]
M173T N/A 3.2 (1.1–11.2) 0.02
VDR (NR1I1) c.1025-49G>T
(ApaI) rs7975232 AIH 0.72
(0.40–1.30) 0.27 123 (214) Caucasian [22]
Intron 8 (BsmI) rs1544410 0.63
(0.37–1.06) 0.08
Exon 2 (FokI) rs1073581 0.5
(0.28–0.92) 0.02
I352I (TaqI) rs731236 1.27
(0.69–2.33) 0.43
c.1025-49G>T
(ApaI) rs7975232 PBC 1.85
(1.02–3.35) 0.04 74 (214)
Intron 8 (BsmI) rs1544410 2.1
(1.22–3.62) 0.006
Exon 2 (FokI) rs1073581 0.55
(0.27–1.12) 0.09
I352I (TaqI) rs731236 1.16
(0.56–2.39) 0.69
c.1025-49G>T
(ApaI) rs7975232 AIH 0.82
(0.42–1.58) 0,55 49 Chinese [20]
Intron 8 (BsmI) rs1544410 1.44
(0.59–3.51) 0.42
Exon 2 (FokI) rs1073581 2.18
(1.07–4.43) 0.019
I352I (TaqI) rs731236 0.00 (0.00) 0.284 Journal of Lipids
Table 1: Continued.
Gene SNP rs number Disease OR (95% CI) P-value Cohort
(controls) Population Reference
c.1025-49G>T
(ApaI) rs7975232 PBC 0.90
(0.49–1.64) 0.727 58
Intron 8 (BsmI) rs1544410 4.41
(1.29–15.02) 0.01
Exon 2 (FokI) rs1073581 1.30
(0.63–2.68) 0.05
I352I (TaqI) rs731236 0.00 (0.00) 0.224
c.1025-49G>T
(ApaI) rs7975232 PBC 0.71
(0.47–1.08) 0.133 195 (179) Japanese [21]
Intron 8 (BsmI) rs1544410 0.71
(0.44–1.16) 0.179
I352I (TaqI) rs731236 1.02
(1.00–1.04) 0.109
c.1025-49G>T
(ApaI) rs7975232 1.02
(0.52–1.98) 1.000 139 (156) Italian
Intron 8 (BsmI) rs1544410 0.33
(0.12–0.92) 0.039
I352I (TaqI) rs731236 0.94
(0.51–1.75) 0.876
c.1025-49G>T
(ApaI) rs7975232 HBV 3.3 (1–11) 0.05 214 (408) [23]
c.1025-49G>T
(ApaI) rs7975232 HCC 0.852 (0.345–
2.113) n.s. 80 (160) Caucasian [30]
Intron 8 (BsmI) rs1544410 1.711 (0.766–
3.813) n.s.
Exon 2 (FokI) rs1073581 1.338 (0.605–
2.968) n.s.
I352I (TaqI) rs731236 0.491 (0.212–
1.141) 0.09
PPARγ (NR1C3) P12A rs1805192 T2D 0.78
(0.59–1.05) 0.045 333 Scandinavian [40]
1.37 0.04 2,126 (1,124) French [38]
0.12
(0.03–0.52) 0.005 532 (386) Asian Sikh [39]
C161T rs121909245 Obesity 2.33
(1.03–5.29) 0.042 292 (371) Australian [37]
NAFLD 4.606 (3.744–
10.263) 0.003 96 (96) Chinese [46]
LXRα (NR1H3) N/A rs2167079 HDL cholesterol
level N/A 5.13 ×
10
−8 4763
Northern
Finland Birth
cohort 1966
[78]
rs7120118 3.57 ×
10
−8
AR (NR3C4) N/A rs5031002 LDL cholesterol
level N/A 2.37 ×
10
−7
PXR (NR1I2) Intronic rs7643645 NAFLD 3.48
(1.25–10.62) 0.008 188 Argentine [54]
rs2461823 N/A 0.039
−25385 rs3814055 DILI 3.37
(1.55–7.30) 0.0023 51 (64) European [74]
Abbreviations: OR: odds ratio; N/A: not annotated; n.s.: not signiﬁcant.Journal of Lipids 5
the promoter and along the entire coding region of the
HNF4A gene and type 2 diabetes in 49.577 individuals re-
vealed signiﬁcant associations for more than one locus [13].
Nuclear transcription factors are known to undergo
posttranslational modiﬁcations modulating their regulatory
activity, which obviously makes the interpretation of genetic
tests more diﬃcult. Recent ﬁndings of epigenetic modiﬁ-
cation of the HNF4A promoter add an additional layer of
uncertainty and environmental impact. Maternal diet and
aging alter the epigenetic control of a promoter-enhancer
interaction at the Hnf4a gene in rat pancreatic islets [14].
Environmentally induced changes in promoter-enhancer
interactions might represent a key epigenetic mechanism by
which nutrition can inﬂuence NR signaling.
3.CandidateReceptor Studies
3.1. Vitamin D Receptor (VDR/NR1I1). The human vitamin
D receptor (VDR/NR1I1) has been in the focus of research
for over a decade, a main reason being a wide spectrum
of known eﬀects of vitamin D deﬁciency. A second, more
mundane reason might be the availability of four frequent
variants (rs7975232, ApaI; rs1544410, BsmI; rs10735810,
FokI; rs731236, TaqI) amenable to relatively quick and easy
analysis using simple technology that has been available
in every genetics laboratory, restriction fragment length
polymorphism(RFLP)analysis.APubmedsearch(asofJune
7, 2011) on “vitamin D receptor polymorphism” resulted in
1,200 articles, covering a wide-range of associated biochem-
ical processes and diseases ranging from the more obvious
bone density in various species at various ages [15, 16]t o
Parkinson disease [17] within the ﬁrst 20 hits, ulcerative
colitis [18], and inﬂammatory bowel disease [19]. Limit-
ing the search to the liver results in a more manageable set
of less than 30 publications, with a detectable focus on in-
ﬂammatory and autoimmune liver diseases, in particular
autoimmune hepatitis and primary biliary cirrhosis [20–22],
but also hepatitis B virus (HBV) infection [23]( Table 1).
In contrast to the mouse liver, which showed no VDR ex-
pression [3], VDR was detected mainly in the nonparenchy-
mal cells of rat liver, whereas hepatocytes expressed barely
any VDR in murine livers [24]. Human hepatocytes express
VDR, albeit at very low abundance [25]. One of the potential
ligands of hepatic VDR in humans is the secondary bile acid
lithocholic acid, resulting in a repression of bile salt synthesis
by transcriptional repression of cholesterol 7α-hydroxylase
(CYP7A1), the rate-limiting enzyme in bile salt biosynthesis
[26]. The eﬀect is achieved by competing for promoter
binding with HNF4-alpha. This example shows that results
from animal models have to be treated with caution, and
once again illustrates the complex interaction between NR-
regulated pathways in human liver.
Association studies between gene variants and diseases
provide signposts towards genes underlying functional ef-
fects, but do not elucidate how these eﬀects are achieved.
Investigations into the detailed eﬀects of the respective poly-
morphisms in NR are harder to interpret than similar inves-
tigations in other molecules of clearer functional delineation
[27]. Cell-type speciﬁc splicing events might modulate tran-
scriptional activation or ligand binding and cause eﬀects in
a substrate-dependent manner. As an example, a functional
eﬀect of the 3 BsmI polymorphism in intron 8 of the VDR/
NR1I1 gene was shown to have a modulatory function on
epithelial cell proliferation when combined with the eﬀects
of calcium [28]. The FokIp o l y m o r p h i s mo fVDR/NR1I1
results in distinct translation initiation sites and was shown
to have an eﬀect on cell growth inhibition, possibly through
estrogen receptor-α protein repression in a cancer cell line
[29].Thesepleiotropicandhighlyvariablefunctionsgosome
way towards explaining the miscellany of associations that
have been detected for VDR polymorphisms, among others
with the occurrence of hepatocellular carcinoma (HCC) in
patients with liver cirrhosis, particularly in patients with an
alcoholic etiology [30]. They also show why the idea of using
NR as a handle towards personalized treatment of patients
is not straightforward, due to the high number of unspeciﬁc
side eﬀects.
3.2. FXR: The Central Bile Salt Sensor. FXR/NR1H4 is the
hepaticnuclearbilesaltreceptor,regulatingbilesaltsynthesis
and transport in hepatocytes, the central hub of cholesterol
synthesis and conversion. Bile salts are direct FXR ligands
and bind to the ligand binding domain of the molecule at
low concentrations as dimers with the retinoid X receptor
(RXR/NR2B1). Upon binding of the heterodimer, confor-
mational change causes FXR activation. FXR also controls
enterohepatic circulation through regulation of intestinal
bile salt uptake via expression of the intestinal bile acid
binding protein (I-BABP) in enterocytes. At the same time,
FXR increases expression and release of ﬁbroblast growth
factor19(FGF19,mouseorthologueFGF15),whichprovides
a feedback regulation loop from the intestine to the liver
via association with β-klotho and activation of its dedicated
receptor FGFR4 (Figure 2). In the liver, dimerization with
RXR induces the expression of various genes involved in bile
salt transport from the hepatocyte into the bile canaliculus
such as the phosphatidylcholine ﬂoppase ABCB4 and the
bile salt export pump ABCB11. Interaction of FXR with the
short heterodimer partner (SHP/NR0B2) decreases bile salt
synthesisbyrepressionofCYP7A1andCYP8B1.Hence,FXR
occupies a key role and is a prime target for manipulating
the balance of bile salts in multiple parts of the enterohepatic
circulation. However, results from a pilot experiment
assessing the metabolic impact of a synthetic FXR agonist
indicate that caution is warranted. The administration of
GW4064-induced obesity and diabetes in mice fed a high-fat
diet and worsened the metabolic eﬀects in liver and adipose
tissue [31].
A potential role of FXR dysregulation in gallstone for-
mation could be shown in the FXR deﬁcient mouse. Due to
the lack of positive feedback via FXR, the hepatocanalicular
transporters ABCB4 and ABCB11 are not induced by bile
salts (Figure 2)[ 32]. Under normal circumstances, biliary
cholesterol is solubilized in mixed micelles, consisting of
cholesterol, phosphatidylcholine, and bile salts. Lack of the
latter two constituents causes supersaturation of cholesterol
andtheprecipitationofcrystalsintheFXR-knockoutmouse.6 Journal of Lipids
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When administered to gallstone-susceptible wild-type mice,
the FXR agonist GW43456 reinstated the biliary balance of
cholesterol, phospholipids, and bile salts by induction of he-
patocanalicular transporter expression [32]. This makes FXR
a potential target for the treatment of cholesterol gallstones.
3.2.1. FXR Variation and Functional Conservation. As u r v e y
of genetic variation in 13 NR that control the expression of
drug metabolizing enzymes revealed an intriguing paucity
of known functional variants in the coding region of FXR/
NR1H4, comparable only in numbers to the androgen re-
ceptor (AR/NR3C4) and the aryl hydrocarbon receptor
(AHR)[33].Thisscarcityhasbeenspeculatedtobeindicative
of considerable evolutionary selective pressures that con-
serve the functional domains in these receptors. However,
compared to the both aforementioned receptors with low
frequencyoffunctionalpolymorphismsinthecodingregion,
FXR revealed a relatively high number of base substitutions
in the regulatory sequence. Thus, protein abundance of the
molecule appears to be more variable than its conformation.
Comparison of the frequency of variants in the sequences
of drug metabolizing CYP enzymes with the frequency
in essential enzymes in protein biosynthesis (ribosomal
genes) and NR genes revealed similar patterns. A high level
of variation in the regulatory sequence and a high conser-
vation in coding areas of NR genes was juxtaposed by a
reversedistributioninribosomalgenes[33].Nodiﬀerencein
variation frequency was observed in the noncoding, intronic
areas.
3.2.2. FXR Variation in Complex Disease. Quantitative trait
locus mapping in inbred mice identiﬁed the Nr1h4 gene
encoding murine Fxr as a candidate gene for a gallstone
susceptibility (lithogenic) locus (Lith7). Sequencing, geno-
typing, and haplotype analysis in humans revealed no more
than three frequent haplotypes accounting for >95% of the
variability. Kovacs et al. [34] described an association of a
common risk haplotype NR1H4 1 (−20,647T; −1G; IVS7-
31A) with gallstones in Mexican patients (OR = 2.1, P =
0.02) (Table 1). The association was inconsistent between
diﬀerent populations, pointing to a minor contributory role
of FXR in overall gallstone susceptibility. Sequence variants
of FXR have also been investigated in other pathological
liverconditions,suchasintrahepaticcholestasisofpregnancy
(ICP). ICP is an interesting model disease as it illustrates the
step up in complexity from monogenic diseases like severe
familial cholestasis in children to complex cholestatic syn-
dromes.ThecentralroleofFXRinbalancingbilesaltconcen-
trations throughout the enterohepatic circulation makes it a
good candidate for investigations into the causes of bile salt
imbalancesduring pregnancy. Van Mil et al.[35]usedanele-
gant and convincing experimental setup to prove the molec-
ular impact of the few variants found in or near the tran-
scribed sequence of FXR: They could show how two disease-
associated single nucleotide polymorphisms (SNPs) at the
methionine start codon or its immediate vicinity resulted in
decreased translation. Expanding beyond the mere quantita-
tive change, van Mil et al. [35]w e n to na n dp r o v e dt h a td e -
creased translation diminished or abolished transactivationJournal of Lipids 7
of FXR target genes in response to bile salt stimulation. A
similar eﬀect could be shown for the only nonconservative
sequence variant that was found in both ICP patients and
unaﬀected controls [35]( Table 1). Marzolini et al. [36]
were able to conﬁrm an eﬀect of this variant in vivo by
examining samples from a human liver bank. The expression
levels of the FXR target genes short heterodimer partner
(SHP/NR0B2) and organic anion transporting polypeptide
1B3(OATP1B3)werereducedinliversharboringtherare[T]
allele at position −1 of the FXR-coding sequence.
3.3. PPAR-Gamma and Diabetes. The peroxisome prolifer-
ator-activated receptor gamma (PPARG/NR1C3) is a fatty
acid-activated member of the PPAR subfamily of NR. These
receptors play important roles in lipid and glucose meta-
bolism. Members of the family have been implicated in
obesity-related metabolic diseases such as hyperlipidemia,
insulin resistance, and coronary artery disease. Like FXR,
PPARsformheterodimerswithRXR,andtheseheterodimers
regulate the transcription of various genes in liver. Poly-
morphisms in PPARG, particularly the proline-to-alanine
substitution at aminoacid position 12, have been associated
with diabetes, insulin levels, insulin sensitivity, body mass
index, and dyslipidemia [37–40]( Table 1).
Disease prediction for population subgroups based on a
combined “diabetes risk matrix” including PPARG p.P12A
has been proposed to be informative and might, if accom-
panied by lifestyle intervention, prove a worthwhile path
for prevention [41, 42]. Genome-wide association studies
(GWAS) of type 2 diabetes in 2,335 Finns conﬁrmed a
contributory role of PPARG [43]. In a comprehensive exam-
ple of complementarity between human and animal model
research, Heikkinen et al. [44] were able to show that the
p.P12A variant exerts its impact on various aspects of meta-
bolism and human longevity in a diet-dependent man-
ner. Hence, this prominent member of the NR family of
molecules is a leading example of gene × environment in-
teraction and “nature via nurture”.
3.4. PPAR-Gamma and NAFLD. Meirhaeghe et al. [45]d e -
scribed an association of a silent SNP in exon 6 of the PPARG
gene (c.C161T) and the level of circulating leptin in obesity.
Obese subjects carrying at least one [T] allele displayed
higher plasma leptin levels than homozygous carriers of the
common allele. The [T] allele was also associated with lower
BMI at a given leptin level, indicating a complex inter-
action between PPAR-gamma and leptin signaling. These
ﬁndings could be conﬁrmed and extended by a study in
96 Chinese patients with nonalcoholic fatty liver disease
(NAFLD), which reported an association of this variant with
adiponectin levels and the development of NAFLD [46].
Zhou et al. [47] replicated this ﬁnding in an independent
cohort, demonstrating that PPARG c.C161T and other poly-
morphisms are associated with the levels of tumor necrosis
factor (TNF)-alpha, leptin, and adiponectin in NAFLD.
When patients in Germany (NAFLD and AFLD, n = 363)
[48]a n dI t a l y( N A F L D ,n = 202) [49]w e r ea n a l y z e df o r
the p.P12A variant, the results were less conclusive: German
patients with fatty liver disease of either etiology were more
likely to carry the rare minor allele, but no association was
detected between p.P12A and the severity of steatosis, ne-
croinﬂammation, or ﬁbrosis.
3.5. Interactions between FXR and PPAR-Gamma. Bile salts
are intimately entwined with lipid metabolism, and besides
their well-known role in dietary lipid absorption and choles-
terol homeostasis, evidence is accumulating that the body
usesbloodlevelsofbilesaltsassensorformetabolicprocesses
(reviewed comprehensively by Thomas et al. [50]). Hence,
bile salts have been considered as metabolic signaling
molecules. The decrease in energy expenditure following
reduction of the bile salt pool by treatment of mice with
the FXR-agonist GW4064 is proof of this concept, although
the resulting weight gain and insulin resistance are not a
desirable outcome [31]. The observation that PPAR-gamma
might be induced by FXR in hepatic stellate cells underscores
and highlights the complex interaction between bile salts,
metabolism, inﬂammation, and ﬁbrogenesis [51]. It also
adds weight to the argument that NRs are involved in most
aspects of metabolic regulation and liver cells’ response to
both internal and external stimuli. Further complexity is
added to the spectrum of NR interactions in the liver by
a recent report on the eﬀect of GW4064 on the expression
ofthePPAR-gammacoactivator-1alpha(PGC1α/PPARGC1).
The synthetic agonist GW4064 enhances expression of
PGC1α and thus mitochondrial function, however enhanced
expression of FXR increases PPARGC1 RNA not directly, but
via protection from repression by the atypical corepressor
SHP [52].
3.6. PXR and NAFLD. The pregnane X receptor (PXR/
NR1I2) is known to be involved in the regulation of hepatic
detoxiﬁcation processes. Using PXR knockout and human-
ized mouse models, PXR was found to inﬂuence drug ×
drug interactions, hepatic steatosis, and the homeostasis
of vitamin D, bile salts, and steroid hormones [53, 54].
Investigations into the genetic contribution of the PXR locus
in 188 patients with NAFLD showed an association of two
variants (rs7643645 and rs2461823) with several phenotypes
of the disease, among others ALT levels [54]( Table 1). The
combined analysis of both loci provided information with
regards to disease progression. One of the associated SNPs
(rs7643645) is localized within a potential binding site for
HNF4-alpha,onceagainillustratingtheinteractionsbetween
NR pathways.
3.7.NRandLiverCancer. Liverreceptorhomologue1(LRH-
1, NR5A2) is an orphan member of the NR superfamily, that
is, it has no known endogenous ligand. LRH-1 is involved
in the regulation of genes that participate in steroid, bile
salt, and cholesterol homeostasis [55]. Knockout of Nr5a2 in
mice results in compromised intestinal lipid absorption as
well as defective embryogenesis and cholesterol homeostasis
[56, 57]. Application of dilauroyl-phosphatidylcholine, a
speciﬁc LRH-1 agonist, increased bile salt levels and lowered
hepatic triglyceride and serum glucose concentrations [58].8 Journal of Lipids
In mouse models of type 2 diabetes, the LRH-1 agonist
also decreased hepatic steatosis and improved glucose home-
ostasis, pointing towards a new intervention target for the
treatment of type 2 diabetes. LRH-1 has also been implicated
in the growth of liver tumors via reversal of repression by
SHP: In vitro methylation of the SHP promoter reversibly
decreased transactivation and LRH-1 binding; overexpres-
sion of SHP inhibited HCC foci formation, arrested HCC
tumor growth in xenografted nude mice, and increased the
sensitivity of HCC cells to apoptotic stimuli [59].
3.8. NR and Viral Hepatitis. The replication of hepatitis C
virus (HCV) is linked to lipid droplets, and a combined
genomic/metabolomic analysis of HCV-infected HUH-7.5
cells by RNA sequencing, microarray, and proteomics re-
vealed profound changes in, among others, PPAR signaling
andPXR/RXRactivation[60].Viralreplicationeﬃciencyhas
been linked to variations in cellular bile salt concentrations
using the HCV replicon system [61]. Of note, variants of the
human bile salt that export pump ABCB11 might be associ-
atedwithsustainedvirologicalresponse[62]andprogression
towards liver cirrhosis [63]. In vitro experiments using HCV
replicon-harboring cells have shown that the impact of bile
salts on HCV replication might be through the action of
FXR rather than a direct eﬀect of bile salts themselves [64].
FXR antagonization by guggulsterone blocked the bile salt-
mediated induction of HCV replication, and guggulsterone
alone inhibited basal HCV replication by tenfold [64].
Hence, it seems feasible that HCV uses transcriptional
activationviaFXR.Itwouldcertainlybeofinteresttoanalyze
the HCV-binding of natural FXR variants implicated in
ICP [35]. We speculate that the increased susceptibility for
cholestatic disease might be counterbalanced by decreased
susceptibility to hepatotropic viruses.
Diﬀerential regulation of the pre-C and pregenomic pro-
moters of HBV by members of the NR superfamily (HNF4-
alpha and PPAR-gamma) has been known for some time
[65]. Rami` ere et al. [66] were able to show that FXR-RXR-
heterodimers bind to two motifs on the HBV enhancer II
and core promoter regions, which are characterized by high
homology to the consensus inverted repeat FXR response
elements [66]. The tight connection between hepatotropic
viruses, liver nutrition, and metabolism by means of NR is
intriguing and might reveal new therapeutic targets or even
dietaryrecommendationstooptimizetheeﬃcacyofantiviral
treatment for HBV or HCV infected patients.
3.9. NR and Drug-Induced Liver Injury (DILI). While diet-
induced metabolic overload, alcohol and HCV are the most
common insults to the liver, drug-induced injury (DILI)
is gaining in prominence due to increasing age and mul-
timorbidity of the general population. The likelihood of
medication-induced liver damage increases substantially
beyond the threshold of 50mg per day cumulative ingestion
[67]. The involvement of the bile salt transporter system in
estrogen-induced cholestasis has been observed for a long
time in patients with ICP [35, 68, 69]. Functional variants of
ABCB11 are known to be associated with cholestasis induced
by oral contraceptives and other drugs [70], as reviewed
elsewhere [71].
The role of gene polymorphisms in predisposition to-
wards DILI has been reviewed comprehensively [72, 73].
Suﬃce to say that next to drug-metabolising enzymes, drug
transporters and genes for the immune response to injury,
variants in the NR genes PXR [74]a n dCAR [58, 75,
76] are the most prominent contributors, for example, to-
wards acetaminophen (APAP) toxicity. Evidence comes from
knockoutorknockdownofthesegenes,conferringresistance
to the toxic eﬀects of APAP.
4. The Search for New Targets
4.1. NR and Metabolic Traits. Identifying and quantifying
genes associated with metabolic traits is one of the prime
challenges when devising means to deal with the epidemics
ofdiabetesandmetabolicsyndrome.Thisinformationmight
be used as cost-eﬃcient leverage to identify and motivate at-
risk individuals towards lifestyle changes, but to date there
is no evidence for clinical impact [77]. A long standing ques-
tionwithregardtotheusefulnessofgenomewideassociation
studies (GWAS) has been how to detect the impact of other
than high-frequency low-risk variants. While the setup of
GWAS is a case-control scenario in an otherwise unselected
population, more in-depth information is expected from
longitudinal studies on large cohorts of individuals with
deﬁned but limited genetic heterogeneity. A combination
of results from both approaches might be required: since
GWAS needs to accommodate higher levels of heterogeneity,
and hence a greater variety of factors that inﬂuence the trait
under examination, only factors that reach the threshold
across the total population are identiﬁed. Studies on smaller
cohorts, possibly with less genetic variety due to a relatively
small common founder population, enable researchers to
identify the impact of comparatively rare variants that have
been enriched in the respective population due to a lack
of admixture, while contributory genetic factors that are
not present in the founder population might be missed.
In fact, using large cohorts with relatively small founder
populations have enabled researchers to identify metabolic
risk factorsby GWAS and association mapping. Typing 4,763
individuals from the Northern Finland birth cohort 1966 for
329,091 SNPs identiﬁed 21 genomic loci that were associated
with metabolic traits such as HDL and LDL cholesterol
levels [78]. Besides the “usual suspects” such as a frequent
polymorphism in the NR1H3 gene encoding LXR-alpha,
which aﬀects HDL cholesterol level with an eﬀect size of only
4% but shows a risk allele frequency of 42%, the study also
detected some higher impact rare alleles. A variation in the
gene for the androgen receptor AR (NR3C4)e x e rt e das t r o n g
inﬂuenceonLDLcholesterollevels,withaconsiderableeﬀect
size of 30% set aside a risk allele frequency of only 2% [78]
(Table 1).
4.2.ComplexNRGenetics. Atourpresentstateofknowledge,
the variation of transcript abundance is probably a more
important mechanism underlying disease susceptibility thanJournal of Lipids 9
structural protein alterations by nonsynonymous SNPs [79].
The view of health as a balanced state or equilibrium of
interrelatedgeneexpressionsholdsalotofattractionforliver
homeostasis, with diseases representing “network perturba-
tions” [80]. This view also explains why transcription factors
are more likely to be detected in GWAS studies of quantita-
tive metabolic traits, since they might be master regulators of
multiple other genes. Hence, NR variants impact not just on
their own expression but can rather, via multiple eﬀectors,
exert stronger eﬀects on a complex phenotype.
AGWASwithmorethan2.5millionSNPsin19,840indi-
viduals, with replication in up to 20,632 individuals, identi-
ﬁed more than 30 loci that had an impact on serum LDL
cholesterol, HDL cholesterol, or triglyceride levels. A rare
variant (risk allele frequency 3%) in HNF4A (p.T130I) was
identiﬁed as a new contributory factor for HDL cholesterol
levels, with an eﬀect size of 19% [81].
4.3. Metabolic Traits as Quantitative Trait Loci (QTLs). Tech-
nical progress, particularly the combination of increased
speedanddecreasedcostofgenotypingandexpressionquan-
tiﬁcation, is ushering in systematic approaches to metabolic
traits. Once suﬃciently large numbers of individuals from
any population (humans, animals, or plants) have been
genotyped for markers covering the entire genome, statistics
can be used to calculate the likelihood of correlation between
the inheritance of genotypes and the expression values
of quantiﬁable phenotypes, including the abundance of
transcripts assayed by expression arrays. This methodology,
denoted as “expression quantitative trait loci (eQTL) map-
ping” can be used to unravel gene regulation by association
and identify regulatory networks involving multiple loci. To
extend the information from these large datasets, Schadt
et al. [82] proposed mathematical models and tools to infer
relationships between genes and groups of genes as well as
between gene expression and disease phenotypes. Liu et al.
[83] used data from the mouse phenome database covering
173 mouse phenotypes to map 937 quantitative trait loci
in silico. Phenotypes examined included various metabolic
traits such as fat mass at diﬀerent diets, cholesterol, and
triglyceride levels under normal and atherogenic diet. Ten of
the QTL regions identiﬁed in this study contained candidate
genes that had previously been characterized and shown
to cause metabolic phenotypes in agreement with the trait
used for mapping, serving as a proof of principle for the
application of this methodology.
Anoteofcautionisobviouslyduewhentransferringdata
and results from mouse models into the human genomic
context. Transcriptional regulation, particularly organ-spe-
cificmechanismsandbindingsites,hasdivergedsigniﬁcantly
between man and mouse, probably more so than NR func-
tion [84]. Nevertheless, results from animal models, partic-
ularly knockouts, still provide valuable clues towards un-
expected mechanisms of disease [85, 86].
4.4. Combining the Power of GWAS and eQTL. The identi-
ﬁcation and functional characterization of regulatory SNPs
have encouraged the use of eQTL data for the interpretation
of GWAS results. These genome-wide scans using anony-
mous SNP markers usually detect associations of disease
with polymorphic markers, often in regions without known
candidate genes [87]. For an example we refer to Kathiresan
etal.[81],whoidentiﬁed30locithatcontributedtowardsthe
regulation of three dyslipidemia traits. Increasing knowledge
abouttransregulatoryeﬀectsbyeQTLmighthelptopinpoint
functional mechanisms for these disease-associated variants.
eQTL data enables us to identify a mechanism by which a
SNP controls expression of a remote locus, hence causing
predisposition to disease by allelic variation across long ge-
nomic distances [88].
5. BringingIt Together: FuturePerspectives
Technical advances increase our knowledge regarding the
biochemical and gene-regulatory mechanisms underlying
metabolic diseases. Transgenic animals inform us about gene
function,eQTLstudiesinhumansamplesandmodelsystems
provide us with information about genetic loci that are
associatedwiththeinheritanceofmultiplemetabolicparam-
eters, and GWAS in genetically well-characterized cohorts
yield candidate genes for metabolic disturbances at ever
increasingresolutionanddepth.Consideringallthisamassed
knowledge, our understanding of disease pathobiology is
improving constantly. Considering the reality of how little
lifestyle modiﬁcation is achieved by risk information, as
illustrated by antismoking campaigns, it remains a challeng-
ing task to employ this knowledge to combat the epidemics
of the metabolic syndrome and its associated burden of
disease.
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